WSU researchers make breakthrough in easing alcohol withdrawal symptoms

Researchers at Washington State University (WSU) have unlocked the answer to curbing alcohol withdrawal symptoms.

A new study found that by targeting the brain’s cerebellum region, scientists were able to lessen debilitating withdrawal symptoms that often trigger relapse.

“By targeting the cerebellum, we were able to ease both the physical motor discoordination and the emotional distress of withdrawal — the symptoms that so often drive people back to drinking,” Nadia McLean, lead author and doctoral researcher in the Department of Integrative Physiology (IPN), said in a post by WSU.

Around 29 million Americans suffer from alcohol use disorder

Alcohol use disorder affects around 29 million Americans, making it the nation’s third-leading preventable cause of death, according to WSU. Less than one in five people with the disorder can maintain long-term sobriety.

While most alcohol disorder research targets the brain’s reward centers, the WSU team examined the cerebellum, which is commonly associated with movement and coordination.

“Half the neurons in the brain are in the cerebellum,” David Rossi, the study’s senior author and associate professor in IPN, said in WSU’s post. “It’s increasingly clear this region is involved in far more than just motor control — it plays a role in addiction, emotional regulation, and even social engagement.”

Scientists discovered chronic alcohol exposure disrupts signaling in the cerebellum, which rewires to function with alcohol. When someone stops drinking, the brain goes into a hyperactive state, leading to withdrawal symptoms. When scientists altered brain function in mice using genetic tools and a specialized compound, physical and emotional symptoms were eased.

“Our research suggests the cerebellum could be a promising therapeutic target to help people get through the most difficult stage of alcohol use disorder,” McLean stated.

Scientists use Compound 6 to ease alcohol withdrawal symptoms in mice

The most promising strategy involved a synthetic compound known as Compound 6. The compound was developed in Austria and targets a receptor in the cerebellum. In mice, the drug eased anxiety without affecting the rest of the brain and showed low potential for abuse.

“Compound 6 gave us a way to target the cerebellum without genetic modification,” McLean stated. “That makes it a much more realistic option for therapy, and it suggests this part of the brain could be a powerful target for treating alcohol withdrawal.”

Clinical trials are still far off, but researchers are hopeful the study will pave the way to make recovery more manageable.

Follow Julia Dallas on X. Read her stories here. Submit news tips here.